PERIOPERATIVE FLOT CHEMOTHERAPY FOR GASTRIC CANCER: A RETROSPECTIVE SINGLE-CENTER COHORT TRIAL

to analyze the short- and long-term outcomes of surgical treatment of patients with gastric cancer who received perioperative chemotherapy (PCT) FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel). A retrospective cohort study included 146 patients who received surgical treatment at the Faculty Surgery Clinic of Sechenov University for gastric cancer (GC) and/or EGJC Sievert Type II-III in the period from January 2018 to December 2022. The main group consisted of 28 patients who received PCT FLOT; there were 118 patients operated "up front" in control group. Patients in both groups did not statistically differ in average age (p=0.110), ASA (p=0.541) and ECOG (p=0.12) status, localization (p=0.063), depth of invasion (p=0.099) and histological structure of tumor (p=0.787). In 92.9% of the patients in the main group and in 94.9% of the control group, R0 resection margins (p=0.750) were achieved. The number of dissected lymph nodes was statistically significantly higher in the main group (average 26 vs 21; p=0.010). There was no difference in intraoperative blood loss (p=0.294) and time of hospital stay (p=0.992); the average duration of surgery in the main group was 319 minutes, compared to 250 minutes in the control group (p